Antoine Babuty

Nantes, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 25 publications

Reply to the Correspondence: "Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses".

Reply to the Correspondence: "Heterogeneity Among Plasma-Derived von Willebrand Factor Concentrates: Implications for Comparative Effectiveness Analyses".

Journal: Seminars in thrombosis and hemostasis

Published: July 23, 2026

Predominance of autoimmune heparin-induced thrombocytopenia in a nephrology department.

Predominance of autoimmune heparin-induced thrombocytopenia in a nephrology department.

Journal: Research and practice in thrombosis and haemostasis

Published: March 25, 2026

Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study.

Vonicog Alfa versus Plasma-Derived von Willebrand Factor During Hospitalization: Results of an Observational Retrospective Multicenter Study.

Journal: Seminars in thrombosis and hemostasis

Published: January 13, 2026

GPVI as a Potential New Biomarker for Myelofibrosis Diagnosis.

GPVI as a Potential New Biomarker for Myelofibrosis Diagnosis.

Journal: American journal of hematology

Published: June 27, 2025

A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice.

A Multispecific Checkpoint Inhibitor Nanofitin with a Fast Tumor Accumulation Property and Anti-Tumor Activity in Immune Competent Mice.

Journal: Biomolecules

Published: January 31, 2025

A new promising anticancer agent: A glycosaminoglycan-mimetic derived from the marine bacterial infernan exopolysaccharide.

A new promising anticancer agent: A glycosaminoglycan-mimetic derived from the marine bacterial infernan exopolysaccharide.

Journal: International journal of biological macromolecules

Published: September 30, 2024

Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice.

Factor VIII restores bone parameters and modulates muscle proteo-metabolome in Factor VIII knockout male mice.

Journal: Bone research

Published: August 29, 2024

Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures.

Efficacy and safety of a recombinant von Willebrand factor treatment in acquired von Willebrand syndrome in case of bleeding and surgical procedures.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: July 08, 2024

Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report.

Bleeding management in type 3 von Willebrand disease with anti-von Willebrand factor inhibitor: A literature review and case report.

Journal: EJHaem

Published: May 16, 2024

Does the VWF:CB Assay Help to Diagnose von Willebrand Factor Deficiency in Patients With a Bleeding Disorder of Unknown Cause?

Does the VWF:CB Assay Help to Diagnose von Willebrand Factor Deficiency in Patients With a Bleeding Disorder of Unknown Cause?

Journal: International journal of laboratory hematology

Published: April 27, 2024

Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs.

Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 04, 2024

Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.

Cyclophosphamide vs rituximab for eradicating inhibitors in acquired hemophilia A: A randomized trial in 108 patients.

Journal: Thrombosis research

Published: November 07, 2023

Showing 1-12 of 25

Last Updated: 09/26/2026